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An author reply to the Letter to the Editor from Tu
et al. regarding Pervasive sequence patents cover
the entire human genome by J Rosenfeld and C
Mason. Genome Med 2013, 5:27.existing DNA cannot be patented, and then also concludedIn our previous work [1], we concluded that patents were
claimed on 21 to 41% of human genes based on long (over
150 nucleotide) fragments, whereas for short (under 150
nucleotide) fragments, we showed their non-specificity
meant that 100% of human genes had some portion pat-
ented. For this analysis, we relied on databases of DNA
sequences included in patents provided by CAMBIA [2]
and the NCBI [3] because we concluded that it is impracti-
cal to manually look through sequence files and patent ap-
plications to determine whether a specific nucleotide
sequence is covered by a patent. While the CAMBIA data-
base [2] includes all sequences present in claims, it does
not distinguish between sequences that are specifically
claimed from those sequences that are merely mentioned
in the claims. Work by Graff et al. [4] estimated that only
8,703 patents on naturally occurring DNA sequences are
still in force. Of those, they estimate that only 3,535 (41%)
are human, indicating that our previous conclusions may
be too broad or could lead to legal conclusions [1] that are
based on an ‘incorrect view of the law’. Yet, subsequent
analysis with the data from CAMBIA has shown many pat-
ents are still in force and leave legal ambiguity [5].* Correspondence: chm2042@med.cornell.edu
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© 2014 BioMed Central Ltd.Nevertheless, the 9–0 Supreme Court decision [6]
reached effectively identical legal conclusions as we did and
rendered this debate moot. The Supreme Court Justices
specifically pointed out (at the bench and in the final deci-
sion) that the issue with short, patented fragments affects
both DNA and cDNA molecules. They concluded that
that cDNA is also non-patentable in cases where it has ‘no
intervening introns to remove when creating cDNA’, or
when it is the length of an exon or less. ‘In that situation, a
short strand of cDNA may be indistinguishable from nat-
ural DNA.’ Thus, when any naturally occurring DNA or
any short cDNA sequence matches the genome, at any size,
it is putatively not patent-eligible, which immediately ad-
dressed the problem of short sequence non-specificity.
Also, Tu et al. claim that it should take only 60 hours
to manually look through the entire set of patents
containing a nucleotide sequence by only looking at the
claims, but this would ignore critical definitions of terms
that often appear in the text of patents. We think that
the actual time required would be much higher, especially if
one were trying to determine whether a sequence involved
in one’s research is patented. It is actually impossible to
manually determine if one’s sequence is close enough to a
claimed sequence, especially since these claims often use
‘homology’ or ‘similarity’ measures defined beyond the
claims’ language. Claim non-specificity is inherent to al-
most all patents on genetic sequences because the precise
ordering of the nucleotides for any gene is probably never
the same between any two people, even for identical twins
or synthesized DNA in a laboratory (owing to enzymatic
errors in copying DNA). Thus, patents on DNA molecules
or cDNA molecules must allow for a wide range of poten-
tial variation of a gene or sequence in order to apply to
every person. To address this problem, many gene-based
patents are written vaguely on purpose, including many we
have previously examined [1].
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patents such as BRCA1, but also for patents granted
even in the past few years [1], such as a broad patent on
JAK2 (number 7,781,199), where the patent covers:
Claim5: “An isolated nucleic acid consisting essentially
of at least 12 consecutive nucleotides of sequence SEQ
ID NO 3 or 4, wherein the isolated nucleic acid
comprises the nucleotide t261 in SEQ ID NO 3 or t50 in
SEQ ID NO 4, wherein the isolated nucleic has the
functional properties of a probe or primer.”
Even though satisfying all elements of the claim seems
to restrict the patent to only fragments with the specified
mutations (t261 or rs77375493), we found that this still ex-
plicitly matches at least 145 other genes [1]. Moreover,
given the loose language in other claims of this patent
(such as Claim 14) that allow for ‘essentially’ the same
molecule, a broad interpretation is possible that could eas-
ily cover thousands of other genes for this one patent.
Yet, while disagreement on the interpretation of these
patents continues, both in press and on blogs (see, for ex-
ample, [7,8]), it is important to remember that this is a
legal debate, not a medical one. This abstract legal debate
is insulated from the pragmatic medical effects of
ambiguous claim language, which have directly led to
cease-and-desist letters ordering scientists and clinicians
to halt research. This includes the halting of scientists’
research focused on BRCA1/2 in the 1990s (as declared by
the plaintiffs in the AMP v. Myriad case [6]). These vague
claims are problematic not only because they are not real
inventions [6], but also because their scope has a direct,
negative impact on clinical research and open access to
fundamental genetic information. Even beyond these vagar-
ies, additional legal problems remain for many gene
patents. First, cDNA synthesis methods, PCR-based ampli-
fication methods and gene sequencing methods are now all
very obvious, dating back to the early 1970s and 1980s,
meaning that remaining patents’ claims may eventually fall
on obviousness grounds. Second, many patents lack meth-
odological specificity and clear enablement because they do
not provide details of an actual set of molecules; rather, they
have ‘invented’ complementary strands of existing mole-
cules and then ‘invented’ any potential variation of that
molecule. If drug patents were written as vaguely as gene
patents, one could imagine ludicrous claims such as ‘X
molecule with 200 atoms, and any variation or combination
of this molecule using 15 or more of its atoms.’ If drug pat-
ents were written so vaguely, it would be almost impossible
to develop new drugs, yet many gene patents and method
claims are built on similarly vague grounds.
Finally, we note the specific novelty and impact of our
k-mer analysis. Previous work in the field had only esti-
mated the number of ‘cross-matches’ from short sequencesor only looked at longer sequences, whereas our work has
empirically detailed the clear non-specificity of both short-
and long-sequence patents. Also, our work noted that many
gene patents have claims ‘for a linear series of nucleotides,
not a specific chemical structure’, and the Supreme Court
explicitly agreed in the final language of their decision [6],
stating that a clear problem with gene patents is that the
‘claims are not expressed in terms of chemical composition’,
rather ‘they focus on the genetic information’. Overall, the
problems highlighted by our data and analysis were mostly
ameliorated by the Supreme Court’s decision [6]. Indeed,
our previous paper’s main conclusion [1], wherein we sug-
gested that the Supreme Court should ‘limit the patenting
of existing nucleotide sequences because of their broad
scope and non-specificity in the human genome’, rather
than being an ‘incorrect view of the law’, is precisely what
happened in the Court, and it is now the law.
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